Nikki M. W. Lee

Nikki M. W. Lee

Auto-generated profile, based on publicly available information

Nikki M. W. Lee

Department of Obstetrics and Gynecology, Prince of Wales Hospital The Chinese University of Hong Kong Hong Kong SAR China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2024 in Circulation
Verified
Journal Article
Open access
LNLong Nguyen-Hoang
Long Nguyen-Hoang
LDLinh Thuy Dinh
Linh Thuy Dinh
ATAngela S.T. Tai
Angela S.T. Tai
DNDuy-Anh Nguyen
Duy-Anh Nguyen
Ritsuko PoohRitsuko Pooh
Ritsuko Pooh
OSOsamu Shimokawa
Osamu Shimokawa
BACKGROUND: This trial aimed to assess the efficacy, acceptability, and safety of a first-trimester screen-and-prevent strategy for preterm preeclampsia in Asia. METHODS: Between August 1, 2019, and February 28, 2022, this multicenter stepped wedge cluster randomized trial included maternity/diagnostic units from 10 regions in Asia. The trial started with a period where all recruiting centers provided routine antenatal care without study-related intervention. At regular 6-week intervals, one cluster was randomized to transit from nonintervention phase to intervention phase. In the intervention phase, women underwent first-trimester screening for preterm preeclampsia using a Bayes theorem-based triple-test. High-risk women, with adjusted risk for preterm preeclampsia ≥1 in 100, received low-dose aspirin from <16 weeks until 36 weeks. RESULTS: Overall, 88.04% (42 897 of 48 725) of women agreed to undergo first-trimester screening for preterm preeclampsia. Among those identified as high-risk in the intervention phase, 82.39% (2919 of 3543) received aspirin prophylaxis. There was no significant difference in the incidence of preterm preeclampsia between the intervention and non-intervention phases (adjusted odds ratio [aOR], 1.59 [95% CI, 0.91–2.77]). However, among high-risk women in the intervention phase, aspirin prophylaxis was significantly associated with a 41% reduction in the incidence of preterm preeclampsia (aOR, 0.59 [95% CI, 0.37–0.92]). In addition, it correlated with 54%, 55%, and 64% reduction in the incidence of preeclampsia with delivery at <34 weeks (aOR, 0.46 [95% CI, 0.23–0.93]), spontaneous preterm birth <34 weeks (aOR, 0.45 [95% CI, 0.22–0.92]), and perinatal death (aOR, 0.34 [95% CI, 0.12–0.91]), respectively. There was no significant between-group difference in the incidence of aspirin-related severe adverse events. CONCLUSIONS: The implementation of the screen-and-prevent strategy for preterm preeclampsia is not associated with a significant reduction in the incidence of preterm preeclampsia. However, low-dose aspirin effectively reduces the incidence of preterm preeclampsia by 41% among high-risk women. The screen-and-prevent strategy for preterm preeclampsia is highly accepted by a diverse group of women from various ethnic backgrounds beyond the original population where the strategy was developed. These findings underpin the importance of the widespread implementation of the screen-and-prevent strategy for preterm preeclampsia on a global scale. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03941886.

23 November 2023 in Best Practice & Research Clinical Obstetrics & Gynaecology
Verified
Journal Article
Closed access
NLNikki M.W. Lee
Nikki M.W. Lee
PCPiya Chaemsaithong
Piya Chaemsaithong
LPLiona C. Poon
Liona C. Poon

5 July 2024 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
NLN. M. W. Lee
N. M. W. Lee
SLS. L. Lau
S. L. Lau
YYY. K. Yeung
Y. K. Yeung
CCC. P. H. Chiu
C. P. H. Chiu
FLF. Liu
F. Liu
LPLiona C. Poon
Liona C. Poon
Objectives: Well‐established clinical practice for assessing progress in labor involves routine abdominal palpation and vaginal examination (VE). However, VE is subjective, poorly reproducible and painful for most women. In this study, our aim was to evaluate the feasibility of systematically integrating transabdominal and transperineal ultrasound assessment of fetal position, parasagittal angle of progression (psAOP), head–perineum distance (HPD) and sonographic cervical dilatation (SCD) to monitor the progress of labor in women undergoing induction of labor (IOL). We also aimed to determine if ultrasound can reduce women's pain during such examinations. Methods: Women were recruited as they presented for IOL in three maternity units. Ultrasound assessments were performed in 100 women between 37 + 0 and 41 + 6 weeks' gestation. A baseline combined transabdominal and transperineal scan was performed, including assessment of fetal biometry, umbilical artery and fetal middle cerebral artery Doppler, amniotic fluid index, fetal spine and occiput positions, psAOP, HPD, SCD and cervical length. Intrapartum scans were performed instead of VE, unless there was a clinical indication to perform a VE, according to protocol. Participants were asked to indicate their level of pain by verbally giving a pain score between 0 and 10 (with 0 representing no pain) during assessment. Repeated measures data were analyzed using mixed‐effect models to identify significant factors that affected the relationship between psAOP, HPD, SCD and mode of delivery. Results: A total of 100 women were included in the study. Of these, 20% delivered by Cesarean section, 65% vaginally and 15% by instrumental delivery. There were no adverse fetal or maternal outcomes. A total of 223 intrapartum ultrasound scans were performed in 87 participants (13 women delivered before intrapartum ultrasound was performed), with a median of two scans per participant (interquartile range (IQR), 1–3). Of these, 76 women underwent a total of 151 VEs with a median of one VE per participant (IQR, 0–2), with no significant difference between vaginal‐ or Cesarean‐delivery groups. After excluding those with epidural anesthesia during examination, the median pain score for intrapartum scans was 0 (IQR, 0–1) and for VE it was 3 (IQR, 0–6). Cesarean delivery was significantly associated with a slower rate of change in psAOP, HPD and SCD. Conclusions: Comprehensive transabdominal and transperineal ultrasound assessment can be used to assess progress in labor and can reduce the level of pain experienced during examination. Ultrasound assessment may be able to replace some transabdominal and vaginal examinations during labor. © 2024 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

2 June 2025 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
HLHiu Yu Hillary Leung
Hiu Yu Hillary Leung
IPIoannis Papastefanou
Ioannis Papastefanou
YCY. Chen
Y. Chen
LNL. Nguyen‐Hoang
L. Nguyen‐Hoang
DND.‐A. Nguyen
D.‐A. Nguyen
LPLiona C. Poon
Liona C. Poon
Objectives: To investigate the impact of aspirin administration on the incidence of preterm birth, according to the type of delivery and gestational age at preterm birth, and to examine the hypothesis that aspirin delays preterm delivery. Methods: This was a secondary analysis of a multicenter stepped‐wedge cluster randomized trial of a first‐trimester screen‐and‐prevent strategy for preterm pre‐eclampsia (PE), which included 18 maternity/diagnostic units in 10 regions across Asia between 1 August 2019 and 28 February 2022. Women deemed to be at high risk for preterm PE according to a Bayes' theorem‐based triple test, i.e. those with an adjusted risk for preterm PE of ≥ 1 in 100, received low‐dose aspirin from < 16 weeks until 36 weeks' gestation. Outcome measures were the incidence of early preterm birth (24 + 0 to 31 + 6 weeks' gestation) and late preterm birth (32 + 0 to 36 + 6 weeks). The treatment effect of aspirin on the rate of preterm birth, stratified by gestational age at birth, type of delivery and presence of pregnancy complications, was estimated by computing the relative risks (RR) between the aspirin and non‐aspirin groups with their 95% CIs. A shift model was designed to evaluate the effect of aspirin on preterm birth, based on the hypothesis that aspirin delays a preterm birth to a more advanced gestational age. Results: In the randomized trial, 42 897/48 647 women accepted screening for preterm PE. Following exclusions, 10 294 and 27 965 women were included in the non‐intervention and intervention phases, respectively. Of the 4688 women at high risk for preterm PE, 2909 (62.05%) received aspirin in the trial. Aspirin was associated with a 42% reduction in the risk of early preterm birth (adjusted relative risk (aRR), 0.577 (95% CI, 0.380–0.852)), and there was a significant upward trend in the rate of late preterm birth accordingly (test for trend, P < 0.01). Similar findings were observed for iatrogenic preterm birth and pregnancies with a small‐for‐gestational‐age neonate. Additionally, aspirin was associated with a 60% reduction in the risk of iatrogenic early preterm birth in pregnancies with PE (aRR, 0.398 (95% CI, 0.192–0.788)). However, aspirin did not have a significant effect on iatrogenic late preterm birth in pregnancies with PE. Aspirin significantly delayed early preterm birth, with the effect decreasing by 0.26 (95% credibility interval, –0.40 to –0.05) weeks for each week of advancing gestation. At 24 weeks, aspirin delayed delivery by 3.63 weeks, while at 37 weeks, the delay was only 0.25 weeks. Conclusions: This secondary explanatory analysis found that early administration of aspirin could effectively reduce the risk of early preterm birth in women at high risk for preterm PE. While the reasons for preterm birth are often multifactorial, this study provides greater insight into the relationship between aspirin and different types of preterm birth at different gestational ages. Our findings support the hypothesis that aspirin helps to prevent preterm birth by delaying the timing of delivery, with a greater impact observed for deliveries that would have occurred at an earlier gestational age had aspirin not been administered. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

29 September 2024 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
IWI. Y. M. Wah
I. Y. M. Wah
DSD. S. Sahota
D. S. Sahota
NWN. K. L. Wong
N. K. L. Wong
NLN. M. W. Lee
N. M. W. Lee
CLC. J. Liu
C. J. Liu
LPLiona C. Poon
Liona C. Poon
Objective: To compare the diagnostic performance of different manufacturers' immunoassays for the soluble fms‐like tyrosine kinase‐1 (sFlt‐1)‐to‐placental growth factor (PlGF) ratio with that of a point‐of‐care (PoC) test for glycosylated fibronectin (GlyFn) in women with suspected pre‐eclampsia (PE).Methods: This was a prospective, single‐center, double‐blinded, non‐interventional study of East Asian women with a singleton pregnancy who presented with hypertension with or without clinical features of PE after 20 weeks' gestation between January 2020 and March 2022. Maternal serum samples were collected at the time of presentation, and subsequent management followed the departmental protocol, based on gestational age, severity of hypertension, fetal condition and presence of severe PE features. Women diagnosed with PE at presentation were excluded. PE was diagnosed according to the 2018 International Society for the Study of Hypertension in Pregnancy classification. Levels of sFlt‐1 and PlGF were measured using the Cobas e411 (Roche Diagnostics), BRAHMS KRYPTOR (ThermoFisher Scientific) and iMAGIN 1800 (Ningbo Aucheer) platforms. GlyFn levels were measured using the Lumella™ GlyFn PoC test (DiabetOmics Inc.). The predictive performance of each test to rule out PE within 7 days and rule in PE within 28 days from the date of presentation was assessed. Based on the PROGNOSIS study, a sFlt‐1/PlGF ratio of ≤ 38 on the Roche platform was used to predict the absence of PE within 7 days. The sFlt‐1/PlGF ratio was classified as high or low using platform‐specific thresholds equivalent to a Roche sFlt‐1/PlGF ratio of 38, which were derived using Passing–Bablok regression. GlyFn was categorized as high or low using two reported clinical management thresholds (263 μg/mL and 510 μg/mL).Results: Overall, 236 women with suspected PE were included, of whom 70 (29.7%) were diagnosed with PE; 36 (51.4%) and 70 (100%) developed PE within 7 days and 28 days, respectively. Eighty‐eight (37.3%) women had a sFlt‐1/PlGF ratio of > 38 on the Roche platform, 79 (33.5%) women had a sFlt‐1/PlGF ratio of > 55 on the KRYPTOR platform and 96 (40.7%) women had a sFlt‐1/PlGF ratio of > 40 on the iMAGIN 1800 platform. Furthermore, 62 (26.3%) and four (1.7%) women had a GlyFn level of > 263 μg/mL and > 510 μg/mL, respectively. The negative predictive value (NPV) of the sFlt‐1/PlGF ratio measured on the Roche, KRYPTOR and iMAGIN 1800 platforms to rule out PE within 7 days after presentation was 83.3%, 82.0% and 82.9%, respectively, while that for GlyFn > 263 μg/mL and > 510 μg/mL was 82.6% and 70.4%, respectively. The corresponding positive predictive values (PPV) to rule in PE within 28 days after presentation were 50.5%, 52.3% and 46.7%, respectively, for the sFlt‐1/PlGF ratio, and 35.4% and 50.0%, respectively, for GlyFn > 263 μg/mL and > 510 μg/mL.Conclusions: The predictive performance of different manufacturers' assays for the sFlt‐1/PlGF ratio to rule in and rule out PE were similar once standardized to a common threshold. Our findings suggest that the sFlt‐1/PlGF ratio and GlyFn using a cut‐off of 263 μg/mL can both be utilized to rule out PE within 7 days after assessment, with a moderate NPV. The PPV for ruling in PE within 28 days remains poor. © 2024 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

1 August 2019 in Clinical Lactation
Verified
Journal Article
Closed access
PDF file
NLNikki Lee
Nikki Lee
Book Review in Clinical Lactation | Volume 10, Issue 3 Biological Nurturing: Instinctual Breastfeeding, 2nd Revised and Updated Edition, by Suzanne Colson Lee, Nikki, BSN, MS, ANLC, IBCLC Clinical Lactation Vol 10 Issue 3 , DOI: 10.1891/2158-0782.10.3.153 Focus Previous Next Article Metrics Article usage Cited by Crossref Google Scholar Focus Previous Next